Mirikizumab with surgery for anal fistulas in Crohn's disease
Treatments studied
Part of Digestive system clinical trials.
This trial is testing whether a drug called mirikizumab, given alongside surgery to repair anal fistulas, can help heal them better in people with Crohn's disease. It aims to provide a new treatment option that may improve healing and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have had Crohn's disease for at least 3 months.
- You must have an active, draining complex anal fistula that is causing symptoms.
- You must be able to understand and agree to participate in the study.
- You cannot have certain other conditions, like active infections, pregnancy, or a stoma.
- You must be able to have an MRI (no implants or other reasons that prevent it).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests mirikizumab to reduce inflammation and symptoms in children with Crohn’s disease that is currently active. It may help if your Crohn’s has not improved enough (or stopped working) with at least one other Crohn’s medicine.
This trial tests a drug called risankizumab (Skyrizi) for people whose Crohn's disease has led to anal fistulas that haven't improved with other treatments. The goal is to see if risankizumab can help these fistulas heal and stop draining.
This study tests a medication called mirikizumab (an injection) in people over 60 with moderate to severe Crohn's disease or ulcerative colitis. The goal is to see if it effectively reduces inflammation and helps symptoms, while also checking how safe it is for older adults.
This study checks whether continuing mirikizumab (a medicine that calms gut inflammation) helps children with ulcerative colitis or Crohn’s disease after prior study treatment. It aims to see if staying on the medicine is beneficial and safe over time.
This trial tests two study drugs, mirikizumab and tirzepatide, in people with moderate to severe Crohn's disease who also have overweight or obesity. The goal is to see if these treatments can help control Crohn's symptoms and inflammation.
This trial tests if mirikizumab can reduce deep inflammation in the intestine walls in people with active Crohn's disease. It may help heal damage that shows up on an MRI scan.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.